FDA Breakthrough Status Ignites Hope for New Friedreich's Ataxia Drug

BALA CYNWYD, PA – February 24, 2026 – In a significant step forward for the rare disease community, Larimar Therapeutics announced today that its investigational drug, nomlabofusp, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). The designation is for the treatment of Friedreich's ataxia (FA), a relentless neurodegenerative disorder, and signals a potential paradigm shift for thousands of patients who currently have limited options.

This regulatory milestone, intended to expedite the development and review of promising new medicines, is coupled with continued positive feedback from the FDA on the company's plan to seek accelerated approval. Larimar is now on a clear path toward a Biologics License Application (BLA) submission targeted for June 2026, bringing what could be the first disease-modifying therapy for FA closer to reality.

A Landmark Designation for a Devastating Disease

Friedreich's ataxia is a cruel and progressive genetic disease that chips away at a person's life. Typically appearing in childhood or adolescence, it relentlessly attacks the nervous system, leading to impaired muscle coordination (ataxia), slurred speech, and profound fatigue. Patients often lose the ability to walk and become reliant on a wheelchair within 10 to 20 years of onset. The disease's reach extends beyond the nervous system, frequently causing life-threatening heart conditions, scoliosis, and diabetes. Globally, an estimated 20,000 people live with FA, including about 5,000 in the United States, a small population facing an immense burden.

Until recently, no approved treatments existed. While the 2023 approval of omaveloxolone offered the first targeted therapy, a profound unmet need remains for a treatment that addresses the root cause of the disease: a deficiency of a crucial mitochondrial protein called frataxin (FXN).

“There continues to be a substantial burden of disease affecting the estimated 5,000 children and adults in the U.S. living with FA,” said Dr. Rusty Clayton, Chief Medical Officer of Larimar, in a statement. “Receiving Breakthrough Therapy Designation underscores the FDA’s recognition of the high unmet medical needs and the potential for nomlabofusp to demonstrate a substantial improvement over available therapy on clinically significant endpoints.”

The Science of Hope: Targeting the Root Cause

Nomlabofusp is engineered to do what no other therapy has done before: directly replace the missing frataxin protein. It is a cleverly designed fusion protein that can penetrate cells and deliver functional human frataxin directly into the mitochondria, the cellular powerhouses where the deficiency causes the most damage. By restoring frataxin levels, the therapy aims to halt or even reverse the cellular dysfunction that drives the disease.

The FDA's decision was based on compelling preliminary data from Larimar's ongoing open-label clinical study. In that study, nomlabofusp not only increased skin frataxin levels to those seen in asymptomatic carriers—individuals who have the gene but no symptoms—but also showed consistent directional improvement across four key clinical measures after one year of treatment. These include the modified Friedreich Ataxia Rating Scale (mFARS), a measure of neurologic function; Activities of Daily Living (ADL); the 9-Hole Peg Test (9-HPT) for hand dexterity; and the Modified Fatigue Impact Scale (MFIS).

These improvements stand in stark contrast to the expected decline observed in a matched patient group from the Friedreich’s Ataxia Clinical Outcomes Measure Study (FACOMS), a large natural history database that tracks the disease's typical progression.

Dr. Marshall Summar, a leading medical geneticist and CEO of Uncommon Cures, a clinical site involved in the study, highlighted the therapy's potential. “The data generated to date suggest that nomlabofusp has the potential to meaningfully impact the underlying biology of the disease and translate into clinically relevant benefits,” he stated. “The clinical improvements observed so far are promising and mark a meaningful step toward what could become the first disease-modifying therapy for a patient population with significant unmet medical needs.”

Forging a Faster Path Through Regulatory Innovation

Breakthrough Therapy Designation is one of the FDA's most powerful tools for accelerating drug development. Reserved for drugs treating serious conditions that show substantial improvement over existing options in early trials, it provides more intensive FDA guidance and eligibility for a faster review timeline. Historically, this designation can shave years off the typical drug development process.

Crucially, Larimar also received continued positive signals from the FDA regarding its innovative clinical trial strategy during a recent meeting under the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. The agency reaffirmed its willingness to consider skin frataxin levels as a "surrogate endpoint"—a marker that is reasonably likely to predict clinical benefit. This is a pivotal agreement, as it allows the company to demonstrate the drug's effectiveness on a biological level without waiting years to measure long-term clinical outcomes, a major hurdle in slowly progressing rare diseases.

The FDA also endorsed Larimar's plan to use a matched reference population from the FACOMS database for comparing clinical endpoint data, further streamlining the path to a BLA submission.

“We are pleased to have continued engagement with the FDA on our planned BLA submission for nomlabofusp and we appreciate FDA’s thorough review of the preliminary clinical data,” said Dr. Carole Ben-Maimon, President and CEO of Larimar. She noted that this progress allows the company to focus on execution and preparing a robust data package for the planned submission.

A Clear Roadmap to Market and Beyond

With the FDA's backing, Larimar has laid out an ambitious but clear timeline. The company expects to release topline data from the open-label study that will support its BLA submission in the second quarter of 2026. In parallel, it plans to initiate screening for a global confirmatory Phase 3 study during the same quarter, with the first patient expected to be dosed by mid-2026.

This confirmatory trial will run concurrently with the BLA review, a strategy aligned with the FDA's guidance for accelerated approval pathways. The planned BLA submission for accelerated approval remains on track for June 2026. If all goes well and the FDA grants approval, a U.S. launch of nomlabofusp is targeted for the first half of 2027.

While the competitive landscape for FA treatments is growing, with several companies pursuing gene therapies and other modalities, nomlabofusp's direct protein-replacement approach is unique. The recent regulatory validation places Larimar in a strong position to potentially deliver a foundational therapy for a community that has been waiting for decades for a treatment that targets the heart of their disease.